Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 6/20 | 0.45 |
| ▸ | PTPN11 | Q06124 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | LCK | P06239 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | BLM | P54132 | 1/20 | 0.39 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | HPGDS | O60760 | 1/20 | 0.36 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.36 |
| ▸ | F7 | P08709 | 1/20 | 0.35 |
| ▸ | F3 | P13726 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2857162 | 0.77 | TSHR (0.54) | PTPN11SMN1; SMN2LCKTSHRMAPT | |
| SCHEMBL2859980 | 0.75 | ALDH1A1 (0.33) | TSHR | |
| SCHEMBL813450 | 0.74 | PARP1 (0.53) | PARP1CYP3A4SMN1; SMN2LCKTSHR | |
| SCHEMBL7077548 | 0.74 | PARP1 (0.60) | PARP1PTPN11CYP3A4SMN1; SMN2TSHR | |
| SCHEMBL259315 | 0.74 | CES2 (0.62) | PARP1PTPN11CYP3A4SMN1; SMN2TSHR | |
| SCHEMBL2996754 | 0.73 | PARP1 (0.48) | PARP1MAPTF7F3SARM1 | |
| SCHEMBL9506862 | 0.72 | LCK (0.45) | PARP1PTPN11CYP3A4SMN1; SMN2LCK | |
| SCHEMBL1799276 | 0.72 | CES2 (0.64) | PARP1PTPN11CYP3A4SMN1; SMN2TSHR | |
| SCHEMBL2088488 | 0.72 | SMN1; SMN2 (0.46) | PARP1CYP3A4SMN1; SMN2LCKTSHR | |
| SCHEMBL31601062 | 0.70 | DHODH (0.48) | PARP1CYP3A4SMN1; SMN2LCKTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4010330-B1 | QUINOLINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | HIRUNDO BIOSCIENCES (BE) | 2025-10-01 | — | — | EP | disclosed |
| US-20220388979-A1 | QUINOLINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | B.C.I. PHARMA (BE) | 2022-12-08 | — | — | US | disclosed |
| US-20220388979-A1 | QUINOLINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | B.C.I. PHARMA (BE) | 2022-12-08 | — | — | US | disclosed |
| EP-4010330-A1 | QUINOLINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | B.C.I. Pharma (BE) | 2022-06-15 | — | — | EP | disclosed |
| CN-114391009-A | Quinoline derivatives as protein kinase inhibitors | BCI制药公司 | 2022-04-22 | — | — | CN | disclosed |
| WO-2021023888-A1 | ISOQUINOLINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | B.C.I. PHARMA (BE) | 2021-02-11 | — | — | WO | disclosed |
| WO-2021023888-A1 | ISOQUINOLINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | B.C.I. PHARMA (BE) | 2021-02-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220388979-A1 | QUINOLINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | ABL1, PHKB, EEF2K | PARP1 1284/4885PTPN11 1612/4885CYP3A4 4406/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.